| Name | Title | Contact Details |
|---|
Zymes is a Hasbrouck Heights, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthonics is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Canada.
We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, Novocure has offices in Germany, Switzerland, Japan and Israel.
Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.